An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation

Schoeberl, Birgit; Faber, Anthony C.; Li, Danan; Liang, Mei-Chih; Crosby, Katherine; Onsum, Matthew; Burenkova, Olga; Pace, Emily; Walton, Zandra; Nie, Lin; Fulgham, Aaron; Song, Youngchul; Nielsen, Ulrik B.; Engelman, Jeffrey A.; Wong, Kwok-Kin

doi:10.1158/0008-5472.can-09-3145

Cited by 264HER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsPI3K/AKT/mTOR signaling in cancer

An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation

Open access

Schoeberl, Birgit, Faber, Anthony C., Li, Danan, Liang, Mei-Chih, Crosby, Katherine, Onsum, Matthew, Burenkova, Olga, Pace, Emily +7 more·2010·Cancer Research

DOI 10.1158/0008-5472.can-09-3145PMC PMC2840205

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

ErbB3 is a critical activator of phosphoinositide 3-kinase (PI3K) signaling in epidermal growth factor receptor (EGFR; ErbB1), ErbB2 [human epidermal growth factor receptor 2 (HER2)], and [hepatocyte growth factor receptor (MET)] addicted cancers, and reactivation of ErbB3 is a prominent method for cancers to become resistant to ErbB inhibitors. In this study, we evaluated the in vivo efficacy of a therapeutic anti-ErbB3 antibody, MM-121. We found that MM-121 effectively blocked ligand-dependent activation of ErbB3 induced by either EGFR, HER2, or MET. Assessment of several cancer cell lines revealed that MM-121 reduced basal ErbB3 phosphorylation most effectively in cancers possessing ligand-dependent activation of ErbB3. In those cancers, MM-121 treatment led to decreased ErbB3 phosphorylation and, in some instances, decreased ErbB3 expression. The efficacy of single-agent MM-121 was also examined in xenograft models. A machine learning algorithm found that MM-121 was most effective against xenografts with evidence of ligand-dependent activation of ErbB3. We subsequently investigated whether MM-121 treatment could abrogate resistance to anti-EGFR therapies by preventing reactivation of ErbB3. We observed that an EGFR mutant lung cancer cell line (HCC827), made resistant to gefitinib by exogenous heregulin, was resensitized by MM-121. In addition, we found that a de novo lung cancer mouse model induced by EGFR T790M-L858R rapidly became resistant to cetuximab. Resistance was associated with an increase in heregulin expression and ErbB3 activation. However, concomitant cetuximab treatment with MM-121 blocked reactivation of ErbB3 and resulted in a sustained and durable response. Thus, these results suggest that targeting ErbB3 with MM-121 can be an effective therapeutic strategy for cancers with ligand-dependent activation of ErbB3.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-09-3145

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Blockade of HER3 with the neutralizing antibody MM-121 increases the efficacy of cetuximab in a mouse model of EGFR mutant lung cancer.
“Consistent with these data, blockade of HER3 with the neutralizing antibody MM-121 increases the efficacy of cetuximab in a mouse model of EGFR mutant lung cancer (Schoeberl et al., 2010).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Schoeberl et al., 2010

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Nature of Statistical Learning Theory
Vapnik, V. (2000) · Statistics for Engineering and Information Science · doi:10.1007/978-1-4757-3264-1 · Cited by 46,387 · see citing works
The Nature of Statistical Learning Theory
Vapnik, V. N. (1995) · doi:10.1007/978-1-4757-2440-0 · Cited by 39,138 · see citing works
An overview of statistical learning theory
Vapnik, V. N. (1999) · IEEE Transactions on Neural Networks · doi:10.1109/72.788640 · Cited by 6,305 · see citing works
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496 · see citing works
Self-citation
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964 · see citing works
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · see citing works
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447 · see citing works
Self-citation
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Sergina, N. V., Rausch, M., Wang, D., Blair, J. A., Hann, B. C., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 993 · see citing works
PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
Engelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1885 · Cited by 730 · see citing works
Self-citation
Support Vector Machines and Kernels for Computational Biology
Ben‐Hur, A., Ong, C. S., Sonnenburg, S., Schölkopf, B., & Rätsch, G. (2008) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000173 · Cited by 703 · see citing works
Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
Yakes, F. M., Chinratanalab, W., Ritter, C. A., King, W., SEELIG, S. A., & Arteaga, C. L. (2002) · PubMed · Cited by 611 · see citing works
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., & Arteaga, C. L. (2001) · PubMed · Cited by 548 · see citing works
ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor.
Soltoff, S. P., Carraway, K. L., Prigent, S. A., Gullick, W. G., & Cantley, L. C. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.6.3550 · Cited by 515 · see citing works
Signaling networks assembled by oncogenic EGFR and c-Met
Guo, A., Villén, J., Kornhauser, J. M., Lee, K. A., Stokes, M. P., Rikova, K., Possemato, A. P., Nardone, J., Innocenti, G., Wetzel, R. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707270105 · Cited by 502 · see citing works
Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network
Ritter, C. A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J. A., & Arteaga, C. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0701 · Cited by 497 · see citing works
Self-citation
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
Engelman, J. A., Janne, P. A., Mermel, C. H., Pearlberg, J., Mukohara, T., Fleet, C., Cichowski, K. M., Johnson, B. E., & Cantley, L. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409773102 · Cited by 494 · see citing works
Self-citation
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors
Bianco, R., Shin, I., Ritter, C. A., Yakes, F. M., Basso, A., Rosen, N. X., Tsurutani, J., Dennis, P. A., Mills, G. B., & Arteaga, C. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206388 · Cited by 449 · see citing works
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer
Zhou, B.-B., Peyton, M., He, B., Liu, C., Girard, L., Caudler, E., Lo, Y. Y. C., Baribaud, F., Mikami, I., Reguart, N., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.05.024 · Cited by 370 · see citing works
Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis
Schoeberl, B., Pace, E. A., Fitzgerald, J. B., Harms, B. D., Xu, L., Nie, L., Linggi, B. E., Kalra, A. V., Paragas, V. B., Bukhalid, R. A., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000352 · Cited by 358 · see citing works
Self-citation
Targeting HER proteins in cancer therapy and the role of the non-target HER3
Hsieh, A. C., & Moasser, M. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603910 · Cited by 269 · see citing works
Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy
Li, D., Shimamura, T., Ji, H., Chen, L., Haringsma, H. J., McNamara, K. L., Liang, M., Perera, S. A., Zaghlul, S., Borgman, C. L., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.06.005 · Cited by 242 · see citing works
Self-citation
ErbB3 Is Involved in Activation of Phosphatidylinositol 3-Kinase by Epidermal Growth Factor
Soltoff, T. P., Carraway, K. L., Prigent, S. A., Gullick, W. G., & Cantley, L. C. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.6.3550-3558.1994 · Cited by 206 · see citing works
Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product.
Kim, H., Sierke, S. L., & Koland, J. G. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31455-2 · Cited by 198 · see citing works
Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein
Sierke, S. L., Cheng, K., Kim, H., & Koland, J. G. (1997) · Biochemical Journal · doi:10.1042/bj3220757 · Cited by 168 · see citing works
Transforming Growth Factor β Engages TACE and ErbB3 To Activate Phosphatidylinositol-3 Kinase/Akt in ErbB2-Overexpressing Breast Cancer and Desensitizes Cells to Trastuzumab
Wang, S. E., Xiang, B., Guix, M., Olivares, M. G., Parker, J. S., Chung, C. H., Pandiella, A., & Arteaga, C. L. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00787-08 · Cited by 165 · see citing works
Neuregulins and Cancer
Montero, J. C., Barrueco, R. R., Ocaña, A., Dı́az-Rodrı́guez, E., Esparı́s-Ogando, A., & Pandiella, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5133 · Cited by 111 · see citing works
The Role of the ErbB Family Members in Non–Small Cell Lung Cancers Sensitive to Epidermal Growth Factor Receptor Kinase Inhibitors
Engelman, J. A., & Cantley, L. C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0795 · Cited by 92 · see citing works
Self-citation
ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib
Frolov, A., Schuller, K., Tzeng, C.-W. D., Cannon, E. E., Ku, B. C., Howard, J. H., Vickers, S. M., Heslin, M. J., Buchsbaum, D. J., & Arnoletti, J. P. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.4.3849 · Cited by 89 · see citing works

Flagged first, then by citations

3 of the 31 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

[17]Burnham KP Anderson DR Model Selection and Multimodel Interference 2 Springer 2002

Sorted by citations

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048 · see citing works
Self-citation
The ERBB network: at last, cancer therapy meets systems biology
Yarden, Y., & Pines, G. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3309 · Cited by 998 · see citing works
Treatment of HER2-positive breast cancer: current status and future perspectives
Arteaga, C. L., Sliwkowski, M. X., Osborne, C. K., Perez, E. A., Puglisi, F., & Gianni, L. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.177 · Cited by 860 · see citing works
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663 · see citing works
Self-citation
Mechanisms of resistance to EGFR tyrosine kinase inhibitors
Huang, L., & Fu, L. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.07.001 · Cited by 596 · see citing works
Targeted therapies for breast cancer
Higgins, M. J., & Baselga, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57152 · Cited by 368 · see citing works
Spatial regulation of receptor tyrosine kinases in development and cancer
Casaletto, J. B., & McClatchey, A. I. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3277 · Cited by 362 · see citing works
A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies
Schaefer, G., Haber, L., Crocker, L., Shia, S., Shao, L., Dowbenko, D. J., Tótpál, K., Wong, A., Lee, C. V., Stawicki, S. S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.003 · Cited by 341 · see citing works
Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread
Pradeep, S., Kim, S. W., Wu, S. Y., Nishimura, M., Chaluvally–Raghavan, P., Miyake, T. M., Pecot, C. V., Kim, S.-J., Choi, H. J., Bischoff, F. Z., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.002 · Cited by 306 · see citing works
Antitumour immunity regulated by aberrant ERBB family signalling
Kumagai, S., Koyama, S., & Nishikawa, H. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-020-00322-0 · Cited by 279 · see citing works
Software for systems biology: from tools to integrated platforms
Ghosh, S., Matsuoka, Y., Asai, Y., Hsin, K., & Kitano, H. (2011) · Nature Reviews Genetics · doi:10.1038/nrg3096 · Cited by 258 · see citing works
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
Abel, E. V., Basile, K. J., Kugel, C. H., Witkiewicz, A. K., Le, K., Amaravadi, R. K., Karakousis, G. C., Xu, X., Xu, W., Schuchter, L. M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65780 · Cited by 242 · see citing works
Recent therapeutic trends and promising targets in triple negative breast cancer
Hwang, S., Park, S., & Kwon, Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.006 · Cited by 233 · see citing works
HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis
Ocaña, A., Vera-Badillo, F., Šeruga, B., Templeton, A. J., Pandiella, A., & Amir, E. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs501 · Cited by 226 · see citing works
Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials
Maennling, A. E., Tur, M. K., Niebert, M., Klockenbring, T., Zeppernick, F. A., Gattenlöhner, S., Meinhold-Heerlein, I. M., & Hussain, A. F. (2019) · Cancers · doi:10.3390/cancers11121826 · Cited by 223 · see citing works
Pharmacological targeting of the pseudokinase Her3
Xie, T., Lim, S. M., Westover, K. D., Dodge, M. E., Ercan, D., Ficarro, S. B., Udayakumar, D., Gurbani, D., Tae, H. S., Riddle, S. M., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1658 · Cited by 205 · see citing works
Molecular Pathways: HER3 Targeted Therapy
Gala, K. P., & Chandarlapaty, S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1549 · Cited by 197 · see citing works
Resistance to HER2-directed antibodies and tyrosine kinase inhibitors
Garrett, J. T., & Arteaga, C. L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.9.15045 · Cited by 179 · see citing works
Targeting of erbB3 receptor to overcome resistance in cancer treatment
Ma, J., Lyu, H., Huang, J., & Liu, B. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-105 · Cited by 176 · see citing works
Treating Breast Cancer in the 21st Century: Emerging Biological Therapies
Tinoco, G., Warsch, S., Glück, S., Avancha, K. K. V. R., & Montero, A. J. (2013) · Journal of Cancer · doi:10.7150/jca.4925 · Cited by 175 · see citing works
HER3 signaling and targeted therapy in cancer
Mishra, R., Patel, H. M., Alanazi, S., Yuan, L., & Garrett, J. T. (2018) · Oncology Reviews · doi:10.4081/oncol.2018.355 · Cited by 175 · see citing works
Mechanisms of action of therapeutic antibodies for cancer
Redman, J. M., Hill, E., Aldeghaither, D. S., & Weiner, L. M. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.04.002 · Cited by 171 · see citing works
Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling
Boeck, A. D., Pauwels, P., Hensen, K., Rummens, J., Westbroek, W., Hendrix, A., Maynard, D., Denys, H. G., Lambein, K., Braems, G., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301393 · Cited by 169 · see citing works
Prospects for pharmacological targeting of pseudokinases
Kung, J. E., & Jura, N. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0018-3 · Cited by 141 · see citing works
Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells
Wang, S., Huang, J., Lyu, H., Lee, C., Tan, M. J., Wang, J., & Liu, B. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.79 · Cited by 128 · see citing works
Understanding the biology of HER3 receptor as a therapeutic target in human cancer
Lyu, H., Han, A., Polsdofer, E., Liu, S., & Liu, B. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.05.010 · Cited by 125 · see citing works
How Genetically Engineered Mouse Tumor Models Provide Insights Into Human Cancers
Politi, K. A., & Pao, W. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8304 · Cited by 122 · see citing works
Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade
Geuijen, C. A. W., Nardis, C. D., Maussang, D., Rovers, E., Gallenne, T., Hendriks, L. J. A., Visser, T., Nijhuis, R., Logtenberg, T., de Kruif, J., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.003 · Cited by 108 · see citing works
Regulation of ERBB3/HER3 signaling in cancer
Mujoo, K., Choi, B.-K., Huang, Z., Zhang, N., & An, Z. (2014) · Oncotarget · doi:10.18632/oncotarget.2655 · Cited by 107 · see citing works
Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance
Zhai, Z., Yu, X., Yang, B. J., Zhang, Y., Zhang, L., Li, X., & Sun, H. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.08.033 · Cited by 106 · see citing works
MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors
Fitzgerald, J. B., Johnson, B. W., Baum, J., Adams, S., Iadevaia, S., Tang, J., Rimkunas, V. M., Xu, L., Kohli, N., Rennard, R., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0255 · Cited by 103 · see citing works
Self-citation
RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation
Mirschberger, C., Schiller, C., Schräml, M., Dimoudis, N., Friess, T., Gerdes, C. A., Reiff, U., Lifke, V., Hoelzlwimmer, G., Kolm, I., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0099 · Cited by 103 · see citing works
Chemotherapy-Resistant Metastatic Breast Cancer
Marquette, C., & Nabell, L. M. (2012) · Current Treatment Options in Oncology · doi:10.1007/s11864-012-0184-6 · Cited by 102 · see citing works
New perspectives on targeted therapy in ovarian cancer
Coward, J. I. G., Middleton, K., & Murphy, F. (2015) · International Journal of Women s Health · doi:10.2147/ijwh.s52379 · Cited by 101 · see citing works
HER3 in cancer: from the bench to the bedside
Gandullo‐Sánchez, L., Ocaña, A., & Pandiella, A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02515-x · Cited by 101 · see citing works
Breast cancer: Current and future endocrine therapies
Palmieri, C., Patten, D. K., Januszewski, A. P., Zucchini, G., & Howell, S. J. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.08.001 · Cited by 100 · see citing works
Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer
Fernandez‐Cuesta, L., & Thomas, R. K. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0854 · Cited by 94 · see citing works
Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib
Yonesaka, K., Hirotani, K., Kawakami, H., Takeda, M., Kaneda, H., Sakai, K., Okamoto, I., Nishio, K., Janne, P. A., & Nakagawa, K. (2015) · Oncogene · doi:10.1038/onc.2015.142 · Cited by 90 · see citing works
Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers
Garrett, J. T., Sutton, C. R., Kurupi, R., Bialucha, C. U., Ettenberg, S. A., Collins, S. D., Sheng, Q., Wallweber, J., Eli, L. D., & Arteaga, C. L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1191 · Cited by 87 · see citing works
The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC ‐γ 1 signalling in breast cancer cell migration and dissemination
Balz, L. M., Bartkowiak, K., Andreas, A., Pantel, K., Niggemann, B., Zänker, K. S., Brandt, B., & Dittmar, T. (2012) · The Journal of Pathology · doi:10.1002/path.3991 · Cited by 87 · see citing works
Novel therapeutic targets for pancreatic cancer
Tang, S.-C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i31.10825 · Cited by 85 · see citing works
Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer
Liu, J. F., Ray-Coquard, I. L., Selle, F., Poveda, A. M., Cibula, D., Hirte, H. W., Hilpert, F., Raspagliesi, F., Gladieff, L., Harter, P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1891 · Cited by 84 · see citing works
The promise of anti-ErbB3 monoclonals as new cancer therapeutics
Aurisicchio, L., Marra, E., Roscilli, G., Mancini, R., & Ciliberto, G. (2012) · Oncotarget · doi:10.18632/oncotarget.550 · Cited by 83 · see citing works
Tumor suppressor miR-22 suppresses lung cancer cell progression through post-transcriptional regulation of ErbB3
Ling, B., Wang, G., Long, G., Qiu, J., & Hu, Z.-L. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1194-2 · Cited by 83 · see citing works
Antibodies directed against receptor tyrosine kinases
Fauvel, B., & Yasri, A. (2014) · mAbs · doi:10.4161/mabs.29089 · Cited by 81 · see citing works
Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block
Jathal, M. K., Chen, L., Mudryj, M. M., & Ghosh, P. (2011) · Immunology Endocrine & Metabolic Agents - Medicinal Chemistry · doi:10.2174/187152211795495643 · Cited by 80 · see citing works
Phenotypic and Molecular Characterization of MCF10DCIS and SUM Breast Cancer Cell Lines
Barnabas, N., & Cohen, D. (2013) · International Journal of Breast Cancer · doi:10.1155/2013/872743 · Cited by 76 · see citing works
ErbB3 Ablation Impairs PI3K/Akt-Dependent Mammary Tumorigenesis
Cook, R. S., Garrett, J. T., Sanchez, V. M., Stanford, J. C., Young, C. D., Chakrabarty, A., Rinehart, C., Zhang, Y., Wu, Y., Greenberger, L. M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3775 · Cited by 76 · see citing works
HER3/ErbB3, an emerging cancer therapeutic target
Zhang, N., Chang, Y., Rios, A. A., & An, Z. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv103 · Cited by 75 · see citing works
Efficient [18F]AlF Radiolabeling of ZHER3:8698 Affibody Molecule for Imaging of HER3 Positive Tumors
Pieve, C. D., Allott, L., Martins, C. D., Vardon, A., Ciobota, D. M., Krämer-Marek, G., & Smith, G. S. T. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00259 · Cited by 75 · see citing works
Current Approaches in NSCLC Targeting K-RAS and EGFR
Aran, V., & Omerović, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225701 · Cited by 74 · see citing works
Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)
Schoeberl, B., Kudla, A. J., Masson, K., Kalra, A. V., Curley, M., Finn, G. J., Pace, E. A., Harms, B. D., Kim, J., Kearns, J. D., et al. (2017) · npj Systems Biology and Applications · doi:10.1038/npjsba.2016.34 · Cited by 73 · see citing works
Self-citation
Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
Watanabe, S., Yonesaka, K., Tanizaki, J., Nonagase, Y., Takegawa, N., Haratani, K., Kawakami, H., Hayashi, H., Takeda, M., Tsurutani, J., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.1995 · Cited by 72 · see citing works
Development of Effective Therapeutics Targeting HER3 for Cancer Treatment
Liu, X., Liu, S., Lyu, H., Riker, A. I., Zhang, Y., & Liu, B. (2019) · Biological Procedures Online · doi:10.1186/s12575-019-0093-1 · Cited by 72 · see citing works
A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer
Mota, J. M., Collier, K. A., Costa, R. L. B., Taxter, T., Kalyan, A., Leite, C. A., Chae, Y. K., Giles, F. J., & Carneiro, B. A. (2017) · Oncotarget · doi:10.18632/oncotarget.18467 · Cited by 70 · see citing works
The E3 ubiquitin ligase NEDD4 negatively regulates HER3/ErbB3 level and signaling
Huang, Z., Choi, B.-K., Mujoo, K., Fan, X., Fa, M.-J., Mukherjee, S., Owiti, N. A., Zhang, N., & An, Z. (2014) · Oncogene · doi:10.1038/onc.2014.56 · Cited by 69 · see citing works
Development of small molecules targeting the pseudokinase Her3
Lim, S. M., Xie, T., Westover, K. D., Ficarro, S. B., Tae, H. S., Gurbani, D., Sim, T., Marto, J. A., Janne, P. A., Crews, C. M., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.04.103 · Cited by 68 · see citing works
HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models
Wang, D., Qian, G., Zhang, H., Magliocca, K. R., Nannapaneni, S., Amin, A. R. M. R., Rossi, M., Patel, M. R., El‐Deiry, M. W., Wadsworth, J. T., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0558 · Cited by 68 · see citing works
ERBB3 is required for metastasis formation of melanoma cells
Tiwary, S., Preziosi, M., Rothberg, P. G., Zeitouni, N. C., Corson, N., & Xu, L. (2014) · Oncogenesis · doi:10.1038/oncsis.2014.23 · Cited by 65 · see citing works
New Strategies in HER2-Overexpressing Breast Cancer: Many Combinations of Targeted Drugs Available
Abramson, V. G., & Arteaga, C. L. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1947 · Cited by 65 · see citing works
Overexpression of HER2/HER3 and clinical feature of ovarian cancer
Chung, Y. W., Kim, S., Hong, J. H., Lee, J. K., Lee, N. W., Lee, Y. S., & Song, J. Y. (2019) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2019.30.e75 · Cited by 64 · see citing works
HER2/HER3 Signaling Regulates NK Cell-Mediated Cytotoxicity via MHC Class I Chain-Related Molecule A and B Expression in Human Breast Cancer Cell Lines
Okita, R., Mougiakakos, D., Ando, T., Mao, Y., Sarhan, D., Wennerberg, E., Seliger, B., Lundqvist, A., Mimura, K., & Kiessling, R. W. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102237 · Cited by 64 · see citing works
The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells
Huang, J., Wang, S., Lyu, H., Cai, B., Yang, X., Wang, J., & Liu, B. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-134 · Cited by 64 · see citing works
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti‐cancer antibodies: IUPHAR Review 18
Carvalho, S., Levi‐Schaffer, F., Sela, M., & Yarden, Y. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13450 · Cited by 64 · see citing works
The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
Yonesaka, K., Kudo, K., Nishida, S., Takahama, T., Iwasa, T., Yoshida, T., Tanaka, K., Takeda, M., Kaneda, H., Okamoto, I., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5286 · Cited by 64 · see citing works
HER3, serious partner in crime
Kol, A., van Scheltinga, A. G. T. T., Timmer‐Bosscha, H., Lamberts, L. E., Bensch, F., de Vries, E. G. E., & Schroder, C. P. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.01.005 · Cited by 61 · see citing works
Dual EGFR/HER2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Withdrawal by Suppressing ErbB3
Chen, L., Mooso, B. A., Jathal, M. K., Madhav, A., Johnson, S. D., Spyk, E. N. V., Mikhailova, M., Ripoll, A. Z., Xue, L., Vinall, R. L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1548 · Cited by 61 · see citing works
Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma
Jiang, N., Wang, D., Hu, Z., Shin, H. J. C., Qian, G., Rahman, M. A., Zhang, H., Amin, A. R. M. R., Nannapaneni, S., Wang, X., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-1093 · Cited by 60 · see citing works
Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
Meetze, K. A., Vincent, S., Tyler, S. M., Mazsa, E. K., Delpero, A. R., Bottega, S., McIntosh, D., Nicoletti, R., Winston, W. M., Weiler, S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2407 · Cited by 56 · see citing works
High Incidence of ErbB3, ErbB4, and MET Expression in Ovarian Cancer
Davies, S., Holmes, A. M., Lomo, L. C., Steinkamp, M. P., Kang, H., Muller, C. Y., & Wilson, B. S. (2014) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000081 · Cited by 56 · see citing works
ERBB3/HER2 Signaling Promotes Resistance to EGFR Blockade in Head and Neck and Colorectal Cancer Models
Zhang, L., Castanaro, C., Luan, B., Yang, K., Fan, L., Fairhurst, J. L., Rafique, A., Potocky, T. B., Shan, J., Delfino, F. J., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-1033 · Cited by 56 · see citing works
Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3
Gaborit, N., Lindzen, M., & Yarden, Y. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1102809 · Cited by 56 · see citing works
Dual-targeted therapy in HER2-positive breast cancer cells with the combination of carbon dots/HER3 siRNA and trastuzumab
Shu, M., Gao, F., Yu, C., Zeng, M., He, G., Wu, Y., Su, Y., Hu, N., Zhou, Z., Yang, Z., et al. (2020) · Nanotechnology · doi:10.1088/1361-6528/ab8a8a · Cited by 56 · see citing works
A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non–EGFR-Mediated Pathways
Rios‐Doria, J., Sabol, D., Chesebrough, J. W., Stewart, D., XU, L. L., Tammali, R., Cheng, L., Du, Q., Schifferli, K. P., Rothstein, R., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1040 · Cited by 55 · see citing works
Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer
Wang, S., Huang, J., Lyu, H., Cai, B., Yang, X., Li, F., Tan, M. J., Edgerton, S. M., Thor, A. D., Lee, C., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3563 · Cited by 53 · see citing works
Advances in Targeting HER3 as an Anticancer Therapy
Jiang, N., Saba, N. F., & Chen, Z. G. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/817304 · Cited by 53 · see citing works
Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients
Brand, T. M., Hartmann, S., Bhola, N. E., Peyser, N. D., Li, H., Zeng, Y., Wechsler, E. I., Ranall, M. V., Bandyopadhyay, S., Duvvuri, U., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2203 · Cited by 53 · see citing works
The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
Majumder, A., Sandhu, M., Banerji, D., Steri, V., Olshen, A. B., & Moasser, M. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-88683-w · Cited by 52 · see citing works
Clinical development of HER3-targeting monoclonal antibodies: Perils and progress
Jacob, W., James, I., Hasmann, M., & Weisser, M. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.06.011 · Cited by 52 · see citing works
Peptide Vaccines and Peptidomimetics Targeting HER and VEGF Proteins May Offer a Potentially New Paradigm in Cancer Immunotherapy
Kaumaya, P. T. P., & Foy, K. C. (2012) · Future Oncology · doi:10.2217/fon.12.95 · Cited by 50 · see citing works
Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2
Maron, R., Schechter, B., Mancini, M., Mahlknecht, G., Yarden, Y., & Sela, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313857110 · Cited by 50 · see citing works
Molecular mechanism matters: Benefits of mechanistic computational models for drug development
Clegg, L. E., & Gabhann, F. M. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.06.002 · Cited by 50 · see citing works
Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer
Mendell, J., Freeman, D. J., Feng, W., Hettmann, T., Schneider, M. B., Blum, S., Ruhe, J. E., Bange, J., Nakamaru, K., Chen, S., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.02.005 · Cited by 49 · see citing works
The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy
Austreid, E., Lønning, P. E., & Eikesdal, H. P. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.885952 · Cited by 49 · see citing works
Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds
Malm, M., Frejd, F. Y., Ståhl, S., & Löfblom, J. (2016) · mAbs · doi:10.1080/19420862.2016.1212147 · Cited by 49 · see citing works
The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions
Odintsov, I., Lui, A. J. W., Sisso, W. J., Gladstone, E., Liu, Z., Delasos, L., Kurth, R. I., Sisso, E. M., Vojnic, M., Khodos, I., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3605 · Cited by 49 · see citing works
Neuregulin/erythroblastic leukemia viral oncogene homolog 3 autocrine loop contributes to invasion and early recurrence of human hepatoma
Hsieh, S., He, J., Hsu, C., Chen, W.-J., Bera, R., Lin, K.-Y., Shih, T., Yu, M.-C., Lin, Y., Chang, C., et al. (2010) · Hepatology · doi:10.1002/hep.24083 · Cited by 47 · see citing works
Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration
Lee, S., Greenlee, E. B., Amick, J., Ligon, G. F., Lillquist, J. S., Natoli, E. J., Hadari, Y. R., Alvarado, D., & Schlessinger, J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518361112 · Cited by 46 · see citing works
Targeting ErbB3-mediated stromal–epithelial interactions in pancreatic ductal adenocarcinoma
Liles, J. S., Arnoletti, J. P., Kossenkov, A. V., Mikhaylina, A., Frost, A. R., Kulesza, P., Heslin, M. J., & Frolov, A. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.263 · Cited by 45 · see citing works
Inhibition of the HER2 pathway by n-3 polyunsaturated fatty acids prevents breast cancer in fat-1 transgenic mice
Zou, Z., Bellenger, S., Massey, K. A., Nicolaou, A., Geissler, A., Bidu, C., Bonnotte, B., Pierre, A.-S., Minville-Walz, M., Rialland, M., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m042754 · Cited by 45 · see citing works
Targeting protein quality control pathways in breast cancer
Sannino, S., & Brodsky, J. L. (2017) · BMC Biology · doi:10.1186/s12915-017-0449-4 · Cited by 42 · see citing works
Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose
Kamath, A. V., Lu, D., Gupta, P., Jin, D., Xiang, H., Wong, A., Leddy, C., Crocker, L., Schaefer, G., Sliwkowski, M. X., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1806-6 · Cited by 41 · see citing works
Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer
Chen, Y. (2013) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2013.01.010 · Cited by 41 · see citing works
A multiscale modeling approach to investigate molecular mechanisms of pseudokinase activation and drug resistance in the HER3/ErbB3receptortyrosinekinasesignaling network
Telesco, S., Shih, A., Jia, F., & Radhakrishnan, R. (2011) · Molecular BioSystems · doi:10.1039/c0mb00345j · Cited by 40 · see citing works
Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network
Lebedeva, G., Sorokin, A., Faratian, D., Mullen, P., Goltsov, A., Langdon, S. P., Harrison, D. J., & Goryanin, I. (2011) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.10.026 · Cited by 40 · see citing works
Anti-HER3 Domain 1 and 3 Antibodies Reduce Tumor Growth by Hindering HER2/HER3 Dimerization and AKT-Induced MDM2, XIAP, and FoxO1 Phosphorylation
Lazrek, Y., Dubreuil, O., Garambois, V., Gaborit, N., Larbouret, C., Clorennec, C. L., Thomas, G., Leconet, W., Jarlier, M., Pugnière, M., et al. (2013) · Neoplasia · doi:10.1593/neo.121960 · Cited by 40 · see citing works
Secreted ERBB3 Isoforms Are Serum Markers for Early Hepatoma in Patients with Chronic Hepatitis and Cirrhosis
Hsieh, S., He, J., Yu, M.-C., Lee, W., Chen, T., Lo, S., Bera, R., Sung, C., & Chiu, C. (2011) · Journal of Proteome Research · doi:10.1021/pr200519q · Cited by 39 · see citing works
Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity
Meulendijks, D., Jacob, W., Voest, E. E., Mau‐Sørensen, M., Martinez‐García, M., Taus, Á., Fleitas, T., Cervantes, A. M. R., Lolkema, M. P., Langenberg, M. H. G., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0812 · Cited by 39 · see citing works
The role of ErbB3 binding protein 1 in cancer: Friend or foe?
Nguyen, D. Q., Hoang, D. H., Vo, T. T. N., Huynh, V., Ghoda, L. Y., Marcucci, G., & Nguyen, L. X. T. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26951 · Cited by 39 · see citing works
Downregulation of HER3 by a Novel Antisense Oligonucleotide, EZN-3920, Improves the Antitumor Activity of EGFR and HER2 Tyrosine Kinase Inhibitors in Animal Models
Wu, Y., Zhang, Y., Wang, M., Li, Q., Qu, Z., Shi, V., Kraft, P., Kim, S. H., Gao, Y. J., Pak, J., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0838 · Cited by 39 · see citing works

Abstract 4945: Targeting ErbB3-addicted cancers across the HER2 spectrum
Onsum, M. D., Yarar, D., Paragas, V. B., Zhang, B., Nguyen, S., Schoeberl, B., McDonagh, C. F., MacBeath, G., & Nielsen, U. B. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-4945 · Cited by 2 · see citing works
Self-citation
MM-121: a human monoclonal antibody ErbB3 antagonist
Schoeberl, B., West, K. A., Leszczyniecka, M., Nie, L., Burenkova, O. V., Linggi, B. E., Fulgham, A., Kudla, A. J., Toth, J., Paragas, V. B., et al. (2008) · Cancer Research
Self-citation
Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis
Schoeberl, B., Pace, E. A., Fitzgerald, J. B., Harms, B. D., Xu, L., Nie, L., Linggi, B. E., Kalra, A. V., Paragas, V. B., Bukhalid, R. A., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000352 · Cited by 358 · see citing works
Self-citation
An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling
Sala, G., Traini, S., D'Egidio, M., Vianale, G., Rossi, C., Piccolo, E., Lattanzio, R., Piantelli, M., Tinari, N., Natali, P. G., et al. (2011) · Oncogene · doi:10.1038/onc.2011.322 · Cited by 36 · see citing works
Effects of an ErbB-3 antibody, MP-RM-1, on tumor growth and ligand-dependent and -independent activation of ErbB-3/akt signaling.
Iacobelli, S., Sala, G., Traini, S., D'Egidio, M., Vianale, G., Rossi, C., Piccolo, E., Lattanzio, R., Piantelli, M., Tinari, N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.e13538

Authors: Schoeberl, B., Faber, A. C., Li, D., Liang, M.-C., Crosby, K., Onsum, M., Burenkova, O., Pace, E., Walton, Z., Nie, L., Fulgham, A., Song, Y., Nielsen, U. B., Engelman, J. A., & Wong, K.-K.
Affiliations: Harvard University (US)
Corresponding author: Engelman, Jeffrey A.
Wong, Kwok-Kin
ORCID: Schoeberl, Birgit
Faber, Anthony C.
Liang, Mei-Chih
Burenkova, Olga
Pace, Emily
Walton, Zandra
Song, Youngchul
Nielsen, Ulrik B.
Engelman, Jeffrey A.
Wong, Kwok-Kin
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2010-03-14
Volume: 70
Issue: 6
Pages: 2485-2494
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-09-3145
PMC: PMC2840205
OpenAlex: W2120213327
Cited by: 264
References: 31
Citations by year: 2026: 2 · 2024: 5 · 2023: 8 · 2022: 11 · 2021: 10 · 2020: 8 · 2019: 10 · 2018: 19 · 2017: 16 · 2016: 26 · 2015: 31 · 2014: 29 · 2013: 29 · 2012: 29
FWCI: 14.05
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute on Aging (R01AG2400401, K08AG024004, R01AG027757)
National Cancer Institute (P50CA127003, CA120060, R01CA122794, R01CA140594, P50CA090578, K08CA120060, R01CA137008)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: HER3, ligand-dependent receptor activation, EGFR, HER2, MET, PI3K signaling, gefitinib resistance, cetuximab resistance, neuregulin-1, EGFR inhibitor resistance, xenograft models
MeSH terms: Cetuximab, Gefitinib, Animals, Antibodies, Monoclonal, Cricetulus, Cricetinae, Humans, Ligands, Neoplasms, Quinazolines, CHO Cells, Neuregulin-1, Receptor, ErbB-3, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Mice, Antibodies, Monoclonal, Humanized, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks